dPCR includes droplet PCR, Bio‐Rad droplet dPCR (ddPCR) platform (Hindson et al., 2011), and BEAMing (beads, emulsion, amplification and magnetics) (Chen et al., 2013): This method is currently among the most promising of targeted approaches, which focuses on the detection of rare mutations in DNA samples with prior knowledge of genetic changes at specific loci of the tumor (e.g., KRAS, BRCA2, ERBB2, and EGFR) (Alix‐Panabieres and Pantel, 2016; Cheng et al., 2017) and exhibits high analytical sensitivity. The gene discussed is ERBB2; the disease is neoplasm.